Boston Scientific Corporation (BSX)

Ameriprise Financial Inc. lessened its stake in shares of Boston Scientific Corporation (NYSE: BSX) by 0.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,786,959 shares of the medical equipment provider's stock after selling 64,744 shares during the quarter. Ameriprise Financial

The latest trading day saw Boston Scientific (BSX) settling at $91.75, representing a -1.02% change from its previous close.

BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

Bank of Nova Scotia boosted its holdings in shares of Boston Scientific Corporation (NYSE: BSX) by 106.4% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,025,519 shares of the medical equipment provider's stock after buying an additional 1,559,605 shares during the period. Boston

Cerity Partners LLC lifted its position in Boston Scientific Corporation (NYSE: BSX) by 0.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,301,504 shares of the medical equipment provider's stock after acquiring an additional 10,625 shares

Baird Financial Group Inc. lifted its stake in Boston Scientific Corporation (NYSE: BSX) by 13.4% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 273,534 shares of the medical equipment provider's stock after acquiring an additional 32,417 shares during the quarter. Baird Financial

Boston Scientific Corporation (NYSE: BSX - Get Free Report) has received an average recommendation of "Buy" from the twenty-five analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, twenty-one have given a buy recommendation and two have issued a strong buy recommendation on the company.

Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript

BSX accelerates growth as a wave of acquisitions boosts core portfolios and fuels expansion into high-growth adjacent markets.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Alcosta Capital Management Inc. purchased a new stake in Boston Scientific Corporation (NYSE: BSX) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 48,427 shares of the medical equipment provider's stock, valued at approximately $5,202,000. Boston Scientific makes up about

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.

Aviso Financial Inc. trimmed its holdings in shares of Boston Scientific Corporation (NYSE: BSX) by 9.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,901 shares of the medical equipment provider's stock after selling 1,540 shares during the period. Aviso Financial